HR Execs on the Move

Intercept Pharmaceuticals

www.interceptpharma.com

 
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients` lives and addressing the liver community`s most pressing needs. Our corporate headquarters is located in New York, and we have additional offices in San Diego, London and Perugia.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Douglas Maneval
Executive Director R&D Quality Profile
Antonio Civitarese
Sr Director, Director of Clinical Research and Development Profile
Michelle Berrey
President R&D and Chief Medical Officer Profile
Dick Lancaster
Vice President, Product Development Profile
Andrew Saik
Chief Financial Officer Profile

Jobs

Director, Human Resources

Intercept Pharmaceuticals San Diego, CA
Accountable for developing and implementing U.S. Regional (San Diego office) HR strategy, in alignment with global HR direction & strategy, to ensure delivery of HR support that enables the U.S. organization to meet or exceed short- and long-term business objectives. While partnering closely with U.S. business operations leaders, areas of ...

Similar Companies

Contract Pharmaceuticals Limited

CPL is a leading contract development and manufacturing organization (CDMO) that provides development, manufacturing, packaging, and testing of non-sterile liquid and semi-solid pharmaceutical and regulated OTC products.

Cabrellis

Cabrellis is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Circle Pharma

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015.

Mirum Pharmaceuticals

Mirum Pharmaceuticals (NASDAQ: MIRM) is dedicated to creating life-changing therapies for patients with liver diseases. We are advancing our lead product candidate for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families. Untreated, these conditions can lead to liver failure and inflict life-altering symptoms including stunted growth and severe, non-stop itching. Under current standard of care, patients often require a liver transplant and are at higher risk of many serious health issues. Working closely with patients and caregiver communities, we intimately understand the challenges of living with cholestatic liver diseases. Based on a wealth of data from clinical trials spanning multiple years and involving more than one hundred patients, we believe our approach can address the underlying cause of symptoms and liver damage. Our goal is to give families their lives back.

Nutraceutics Corp

Nutraceutics Corp is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.